Skip NavigationSkip to Content
Return Return to Search Results

Analysis of vasodilator responses to novel nitric oxide donors in the hindquarters vascular bed of the cat

  1. Author:
    Bivalacqua, T. J.
    Champion, H. C.
    De Witt, B. J.
    Saavedra, J. E.
    Hrabie, J. A.
    Keefer, L. K.
    Kadowitz, P. J.

  2. Author Address

    Tulane Univ, Sch Med, Dept Pharmacol, 1430 Tulane Ave, SL83, New Orleans, LA 70112 USA. Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70112 USA. NCI, Frederick Canc Res & Dev Ctr, Comparat Carcinogenesis Lab, Frederick, MD USA. SAIC Frederick, Frederick, MD USA. Kadowitz PJ Tulane Univ, Sch Med, Dept Pharmacol, 1430 Tulane Ave, SL83, New Orleans, LA 70112 USA.
    1. Year: 2001
  2. Journal: Journal of Cardiovascular Pharmacology
    1. 38
    2. 1
    3. Pages: 120-129
  4. Type of Article: Article
  1. Abstract:

    Controlled release of nitric oxide (NO.) may be useful in the treatment of a variety of vascular disorders. NO. donors of the diazeniumdiolate family with different rates of spontaneous NO. release have been synthesized. In the current study responses to seven diazeniurndiolate NO. donors (DEA/NO., DETA/NO., OXI/NO., PIPERAZI/NO., PROLT/NO., SPER/NO., and SULFI/NO.) were investigated in the hindquarters vascular bed of the cat. Intravenous injections of all NO. donors caused dose-dependent decreases in systemic arterial pressure and the rank order of potency was SNP > DEA/NO. > PIPERAZI/NO. > SPER/NO. > PROLI/NO. > OXI/NO., Injections of all NO. donors into the hindlimb perfusion circuit caused dose-related decreases in hindquarters perfusion pressure that were similar to the order of potency in decreasing systemic arterial pressure. The rank order of the time required for the response to return to 50% of the maximal decrease in pressure (T-1/2) and total duration of action of the NO. donors was SPER/NO. > PIPERAZI/NO. > DEA/NO. > OXVNO. > DETA/NO. > PROLI/NO. > SULFI/NO.. After treatment with the NO. synthase inhibitor, N-omega-nitro-L-arginine methyl ester (100 mg/kg, i.v.), hindlimb vasodilator responses to the NO. donors were not significantly different, but vasodilator responses to acetylcholine were significantly reduced. After treatment with zaprinast (2 mg/kg, i.v.), a type V cyclic 3 ', 5 ' -guanosine monophosphate-specific phosphodiesterase inhibitor, the duration of vasodilator responses to the NO. donors, as measured by T-1/2, was increased significantly, whereas the duration of the response to the beta (2)-adrenergic receptor agonist albuterol was unchanged. These data suggest that diazeniumdiolate NO. donors are endothelium-independent, directly stimulate soluble guanylate cyclase, and decrease vascular resistance by increasing cyclic 3 ', 5 ' -guanosine monophosphate levels in the hindquarters vascular bed of the cat.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel